Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Safety and Efficacy in Schizophrenia
NCT00257023Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of paliperidone in schizophrenia (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Safety assessments including adverse events and DIESS results. Started Feb 2005; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00257023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257023.